Pages Menu
Twitter
Categories Menu

Posted by on Dec 12, 2012 in Neurology, Pharma

Once More Into the Breach: Lilly Plans New Phase 3 Study of Anti-Amyloid MAb in Alzheimer’s

Once More Into the Breach: Lilly Plans New Phase 3 Study of Anti-Amyloid MAb in Alzheimer’s

Olivier_Henry-V.jpgDespite tepid phase 3 results (see here and here), Lilly will continue late-phase development of its anti-amyloid MAb, solanezumab, in patients with mild AD. Today’s company press release says that the new trial will begin “no later than Q3 2013.” Market analysts expect the trial to complete in 2015 (the anticipated length of the trial is presumably the same as that of Lilly’s EXPEDITION studies, 18 months). If successful, the drug would launch in 2017.

Now set the teeth and stretch the nostril wide,
Hold hard the breath and bend up every spirit
To his full height.

Or don’t.

MAb = monoclonal antibody.
bmartin (1130 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.